Alumis Inc. (NASDAQ:ALMS) Receives $26.83 Average Price Target from Analysts

Alumis Inc. (NASDAQ:ALMSGet Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $26.83.

Several research analysts have recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Alumis in a report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Alumis in a research report on Monday, January 6th. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st.

Get Our Latest Stock Report on ALMS

Hedge Funds Weigh In On Alumis

A number of large investors have recently modified their holdings of ALMS. Millennium Management LLC bought a new position in Alumis in the 2nd quarter worth approximately $3,376,000. Maven Securities LTD bought a new position in Alumis in the second quarter valued at approximately $332,000. Towerview LLC boosted its stake in Alumis by 22.6% in the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after acquiring an additional 70,000 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in shares of Alumis in the 3rd quarter valued at $1,160,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Alumis in the 3rd quarter worth $27,000.

Alumis Stock Performance

Shares of NASDAQ:ALMS opened at $6.75 on Friday. The business has a 50 day moving average price of $8.33 and a 200 day moving average price of $10.56. Alumis has a twelve month low of $6.40 and a twelve month high of $13.53.

About Alumis

(Get Free Report

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Featured Stories

Analyst Recommendations for Alumis (NASDAQ:ALMS)

Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.